Corporate / M&A

Healthcare / Life Sciences

IP / IT

Noema Pharma

Homburger News

Share-Image Teamplate Deals-and-Cases

On December 11, 2024, Noema Pharma AG announced that it has successfully closed a Series B extension financing round with an investment from EQT Life Sciences, bringing the total capital raised in the round to CHF 130 m (approx. USD 147 m). With its investment in Noema Pharma, EQT Life Sciences joins the syndicate of previous Series B investors including Forbion, Jeito Capital, Sofinnova Partners, Gilde Healthcare, Polaris Partners, Invus and UPMC Enterprises.
Noema Pharma is a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders characterized by imbalanced neuronal networks. The new financing will support Noema Pharma&#8217;s four active Phase 2 trials, with key data readouts anticipated in 2025.
Homburger AG advised Noema Pharma AG as transaction counsel in this Series B extension financing round. The Homburger team comprised Andreas Müller, Thierry Burckhardt, Thomas Romelli and Rebecca Sigrist (all Corporate / M&amp;A; Healthcare / Life Sciences), Luca Dal Molin (IP / IT; Healthcare / Life Sciences) as well as Stefan Oesterhelt and Laetitia Fracheboud (Tax).

Homburger advised Noema Pharma AG on its Series B extension financing round

Homburger advised the Kellenberger family on the reduction of its shareholding in Calida Holding AG

The Kellenberger family has significantly reduced its shareholding in Calida Holding AG (the Company) in two transactions, a public buy-back offer and a direct repurchase.
Homburger advised the Kellenberger family on these transactions.
The Homburger team was led by Dieter Gericke and included Hansjürg Appenzeller, Daniel Häusermann, Cédric Berger, Thierry Burckhardt, Caspar Wehrle and Marc Abplanalp (all Corporate / M&amp;A) as well as Reto Heuberger, Arbnor Sheholli and Philipp Stiegeler (all Tax).

Competition

KPMG_web-640x140

On May 24, 2024, KPMG Switzerland and KPMG UK announced that their respective partnerships had voted overwhelmingly in favor of merging their partnerships, creating a new USD 4.4 bn business, working across audit, tax and legal, and advisory. Both firms enter the merger from positions of strength as growing, profitable businesses in their respective home markets and have a long and strong history of working together for multinational clients. With a wider geographic coverage, the new firm will be able to expand its service and sector expertise complementing the already deep local market understanding for its national and international clients.
Homburger AG acted as legal counsel to KPMG Switzerland on the transaction. The Homburger team was led by Daniel Hasler (Corporate / M&amp;A) and included Thierry Burckhardt, Marc Abplanalp, Paula Delissen, Marilena Balthasar, Norina Tröhler (all Corporate / M&amp;A), Richard Stäuber, Erik Habich (both Competition), and Stefan Oesterhelt (Tax).

Thierry
Burckhardt

Homburger advised Noema Pharma AG on its Series B extension financing round

Homburger advised the Kellenberger family on the reduction of its shareholding in Calida Holding AG

Homburger advised KPMG Switzerland on its merger with KPMG UK

Private Equity 2024: Switzerland

Join the Team

Thierry Burckhardt

Career

Languages

Bar Registration

Teams

ThierryBurckhardt

Homburger advised Noema Pharma AG on its Series B extension financing round

Homburger advised the Kellenberger family on the reduction of its shareholding in Calida Holding AG

Homburger advised KPMG Switzerland on its merger with KPMG UK

Private Equity 2024: Switzerland

Join the Team

Thierry Burckhardt

Career

Languages

Bar Registration

Teams

Thierry
Burckhardt